Around the world, 329 million people are living with the symptoms of chronic obstructive pulmonary disease (COPD) and a further 358 million people suffer from asthma. For over 45 years GSK has been focusing on helping patients like Alison, Donna and Jose to breath better.
We remain at the cutting-edge of scientific research into respiratory medicine, investing more than any other company and working in collaboration with patients and the scientific community to offer innovative medicines aimed at helping to treat patients’ symptoms and reduce the risk of their disease worsening.
For example, by incorporating patient and physician feedback we have ensured our innovative new inhaler is not only effective but also easy to use. We have the broadest portfolio of once-daily medicines in a single inhaler type, which is the result of decades of development. We’re also exploring how the growing ‘internet of things’ can help us to bring smart sensor technology into our respiratory research, medicines and devices.
Innovating to fight respiratory diseases
329 million people suffer from COPD worldwide. A further 358 million suffer from asthma. We are on a journey to help everyone breathe better and live the life they want.